Welcome to the 10th Annual Innate Killer Summit
Celebrating a Decade of Uniting the NK Cell Therapy Community!
As the NK community remains determined as ever to prove the advantages of NK cells, the year of the ‘bounce back’ now feels within reach. Driven by expansion into autoimmune pipelines, Artiva’s $160M IPO marks a sizeable return of investment into this space. It is now business critical for NK developers to capitalize on the new momentum building and showcase clinically validated pipelines to investors to demonstrate the potential of NK therapies and bring long lasting benefit to patients in need.
Returning to San Diego for its 10th Anniversary, the 10th Annual Innate Killer Summit continues to unite long-standing senior pioneers and trailblazers in the NK space. As the only dedicated platform to advancing development of NK engager, NK bispecific, cell therapy and cytokine-based approaches to the clinic with improved persistence and efficacy, you won’t want to miss out.
Join 30+ wave-makers including Indapta Therapeutics, Genentech, Katy Rezvani’s Lab and Artiva Bio as they pave the way to revolutionizing allogeneic and innate immunity treatment.
What's *NEW* for 2025?
In our Preclinical Development Stream, focus on CAR-NK constructs, NK cell localizations and overcoming the TME
Unveil the latest clinical data to boost efficacy and expand NKs in the Clinical Manufacturing & Development Stream
Explore the cutting-edge approaches in using NK engagers for autoimmune disease at our new Applications of NK Biology to Autoimmunity Focus Day
For the first time hear from Genentech, Angeles Therapeutics, Takeda, Chimeric Therapeutics, Indaptus Therapeutics & UCL
"As a mother to a child with cancer, and the Co-Founder of an NK cell company, this event allows me to meet other thought leaders, stakeholders, and likeminded people on the same mission to end cancer and other life-threatening diseases”
Chief Communications Officer, NKore Biotherapeutics
Our World-Class Speaker Faculty Includes:
“It's a wonderful meeting to connect many scientists focusing on the NK cell
therapy worldwide”
Chief Technical Officer, Apexcella
Previously Attending Companies Include:
Our 2025 Partners:
Other Events in the Series:
"This event brings top companies in NK field globally working on diverse areas. This
is very helpful to understand the challenges and allows us to do any course
correction early, if needed”
Chief Executive Officer & Co-Founder, East Ocyon Bio
